Biotech Acquisition Company Unit
BIOTU
BIOTU was delisted on the 2nd of February, 2023.
0 hedge funds and large institutions have $0 invested in Biotech Acquisition Company Unit in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 5 closing their positions.
100% less funds holding
Funds holding: 5 → 0 (-5)
100% less capital invested
Capital invested by funds: $540K → $0 (-$540K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$401K |
| 2 |
VF
Virtu Financial
New York
|
-$130K |
| 3 |
Morgan Stanley
New York
|
-$5.53K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.11K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
BIOTU Hedge Fund Activity: Q1 2023 in Review
0 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Unit (BIOTU) for Q1 2023, worth a combined $0 — down 100% from $540K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BIOTU and 0 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Millennium Management, exiting entirely with an estimated $401K sold.
- 0 institutional investors held Biotech Acquisition Company Unit (BIOTU) as of Q1 2023, down from 5 in Q4 2022.
- Funds reported $0 of Biotech Acquisition Company Unit stock for Q1 2023, down 100% quarter-over-quarter.
- 0 funds opened new Biotech Acquisition Company Unit positions in Q1 2023 and 5 closed out, a net change of -5 holders.
- The largest Biotech Acquisition Company Unit seller in Q1 2023 was Millennium Management, an estimated $401K sold.
Based on aggregated 13F filings for Q1 2023.